
David Pirlot
Examiner (ID: 12288)
| Most Active Art Unit | 3202 |
| Art Unit(s) | 2833, 3202 |
| Total Applications | 1812 |
| Issued Applications | 1572 |
| Pending Applications | 21 |
| Abandoned Applications | 219 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17895362
[patent_doc_number] => 20220305024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => TREATMENT FOR AORTIC ANEURYSMS
[patent_app_type] => utility
[patent_app_number] => 17/616122
[patent_app_country] => US
[patent_app_date] => 2020-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13219
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616122
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616122 | Treatment for aortic aneurysms | Jun 2, 2020 | Issued |
Array
(
[id] => 19675887
[patent_doc_number] => 12187737
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Imidazolo derivatives, compositions and methods as orexin antagonists
[patent_app_type] => utility
[patent_app_number] => 17/616152
[patent_app_country] => US
[patent_app_date] => 2020-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14761
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 525
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616152
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616152 | Imidazolo derivatives, compositions and methods as orexin antagonists | Jun 2, 2020 | Issued |
Array
(
[id] => 20452986
[patent_doc_number] => 12516036
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
[patent_app_type] => utility
[patent_app_number] => 17/613983
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 1216
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613983
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/613983 | Crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative | May 28, 2020 | Issued |
Array
(
[id] => 17748116
[patent_doc_number] => 20220226319
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => TALTIRELIN USE
[patent_app_type] => utility
[patent_app_number] => 17/595843
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4662
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17595843
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/595843 | TALTIRELIN USE | May 28, 2020 | Pending |
Array
(
[id] => 16506148
[patent_doc_number] => 20200385404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => SYNTHESIS OF CEPHALOSPORIN COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/880223
[patent_app_country] => US
[patent_app_date] => 2020-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15950
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880223
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/880223 | Synthesis of cephalosporin compounds | May 20, 2020 | Issued |
Array
(
[id] => 19120995
[patent_doc_number] => 11964965
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-23
[patent_title] => Methods of manufacture and synthesis of fluorescent dye compounds and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/879569
[patent_app_country] => US
[patent_app_date] => 2020-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 26
[patent_no_of_words] => 6778
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 209
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16879569
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/879569 | Methods of manufacture and synthesis of fluorescent dye compounds and uses thereof | May 19, 2020 | Issued |
Array
(
[id] => 17851844
[patent_doc_number] => 20220281886
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/611553
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19190
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611553
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/611553 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | May 17, 2020 | Abandoned |
Array
(
[id] => 16390933
[patent_doc_number] => 20200331874
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/872114
[patent_app_country] => US
[patent_app_date] => 2020-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45399
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872114
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/872114 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | May 10, 2020 | Issued |
Array
(
[id] => 16343520
[patent_doc_number] => 20200308170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => KRAS G12C INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/869079
[patent_app_country] => US
[patent_app_date] => 2020-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65952
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869079
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/869079 | KRAS G12C INHIBITORS | May 6, 2020 | Abandoned |
Array
(
[id] => 16253463
[patent_doc_number] => 20200262837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => KRAS G12C INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/868258
[patent_app_country] => US
[patent_app_date] => 2020-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 245258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 514
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868258
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/868258 | KRAS G12C INHIBITORS | May 5, 2020 | Abandoned |
Array
(
[id] => 17733236
[patent_doc_number] => 20220218695
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA
[patent_app_type] => utility
[patent_app_number] => 17/610007
[patent_app_country] => US
[patent_app_date] => 2020-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8637
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610007
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/610007 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | May 3, 2020 | Pending |
Array
(
[id] => 16450949
[patent_doc_number] => 20200360375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => SMALL MOLECULE WNT INHIBITOR AS TREATMENT FOR DYSLIPIDEMIA
[patent_app_type] => utility
[patent_app_number] => 16/864521
[patent_app_country] => US
[patent_app_date] => 2020-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25810
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864521
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/864521 | Small molecule Wnt inhibitor as treatment for dyslipidemia | Apr 30, 2020 | Issued |
Array
(
[id] => 17749533
[patent_doc_number] => 20220227737
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
[patent_app_type] => utility
[patent_app_number] => 17/607430
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40083
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607430
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/607430 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | Apr 28, 2020 | Abandoned |
Array
(
[id] => 17837623
[patent_doc_number] => 20220274928
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => PAPD5 INHIBITORS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/605763
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53335
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 518
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605763
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605763 | PAPD5 inhibitors and methods of use thereof | Apr 22, 2020 | Issued |
Array
(
[id] => 18399294
[patent_doc_number] => 11661420
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-30
[patent_title] => Compound containing fused ring, use thereof and pharmaceutical composition containing same
[patent_app_type] => utility
[patent_app_number] => 17/594524
[patent_app_country] => US
[patent_app_date] => 2020-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25244
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 222
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594524
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594524 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | Apr 21, 2020 | Issued |
Array
(
[id] => 19855516
[patent_doc_number] => 12258338
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Modulators of the integrated stress response pathway
[patent_app_type] => utility
[patent_app_number] => 17/605037
[patent_app_country] => US
[patent_app_date] => 2020-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47845
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 986
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605037
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605037 | Modulators of the integrated stress response pathway | Apr 21, 2020 | Issued |
Array
(
[id] => 16695449
[patent_doc_number] => 10946018
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Spirocyclic compounds as tryptophan hydroxylase inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/850542
[patent_app_country] => US
[patent_app_date] => 2020-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 120777
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16850542
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/850542 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Apr 15, 2020 | Issued |
Array
(
[id] => 16680696
[patent_doc_number] => 10940152
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-09
[patent_title] => Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
[patent_app_type] => utility
[patent_app_number] => 16/846503
[patent_app_country] => US
[patent_app_date] => 2020-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36011
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 311
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846503
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/846503 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | Apr 12, 2020 | Issued |
Array
(
[id] => 17640575
[patent_doc_number] => 20220168313
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => HETEROCYCLIC COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/594299
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21600
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594299
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594299 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Apr 7, 2020 | Abandoned |
Array
(
[id] => 16189311
[patent_doc_number] => 20200230160
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => BORON-CONTAINING SMALL MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/840239
[patent_app_country] => US
[patent_app_date] => 2020-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51730
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 474
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840239
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/840239 | Boron-containing small molecules | Apr 2, 2020 | Issued |